TAI · 4106.TW
Wellell Inc.
NT$23.35-NT$0.55 (-2.3%)
Wellell Inc.’s quoted price sits in the lower half of its reported 52-week range, 9.85% below the high.
Loading market information…
TWO · 6527.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Crystalvue Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 13.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Crystalvue Medical Corporation’s forward annual dividend is NT$2.90 per share, paid annual. The forward yield is 4.02% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Crystalvue Medical Corporation’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of NT$1.19. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Crystalvue Medical Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Taoyuan City, Taiwan, and established in 2009, Crystalvue Medical Corporation operates internationally, specializing in the design, production, and distribution of ophthalmic medical devices. Their comprehensive product range encompasses instruments like retinal cameras, tonometers, and lens edgers, in addition to various gastroenterology provisions.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| NT$1.32 |
| NT$233.09M |
| Q2 2024 | Aug 5, 2024 | NT$1.28 | NT$211.41M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$23.35-NT$0.55 (-2.3%)
Wellell Inc.’s quoted price sits in the lower half of its reported 52-week range, 9.85% below the high.
NT$55.70+NT$0.80 (+1.46%)
TSH Biopharm Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 6.07% below the high.
NT$44.20+NT$1.35 (+3.15%)
BenQ Medical Technology Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.42% below the high.
NT$31.45+NT$0.55 (+1.78%)
DIVA Laboratories, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 16.8% below the high.
NT$28.50-NT$0.15 (-0.52%)
Chi Sheng Pharma & Biotech Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 7.92% below the high.
NT$57.80-NT$0.60 (-1.03%)
Greenyn Biotechnology Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 25.9% below the high.
NT$53.20-NT$0.20 (-0.37%)
Medical Imaging Corporation’s quoted price sits in the lower half of its reported 52-week range, 36.06% below the high.
NT$32.15+NT$0.45 (+1.42%)
Lagis Enterprise Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.57% below the high.
